Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials

Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐base...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2021-05, Vol.123 (6), p.1467-1474
Main Authors: Essaji, Yasmin, Rocha, Flavio G.
Format: Article
Language:English
Subjects:
adjuvant chemoradiation
adjuvant chemotherapy
Cancer therapies
Carcinoma, Pancreatic Ductal - drug therapy
Carcinoma, Pancreatic Ductal - radiotherapy
Carcinoma, Pancreatic Ductal - surgery
Carcinoma, Pancreatic Ductal - therapy
Chemoradiotherapy, Adjuvant
Clinical Trials, Phase III as Topic
evidence‐based medicine
Humans
Neoadjuvant Therapy
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - radiotherapy
Pancreatic Neoplasms - surgery
Pancreatic Neoplasms - therapy
Randomized Controlled Trials as Topic
Surgical Oncology - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.26382